Article Listing - Bayer’s regorafenib shows promise in renal cancer, may fuel Onyx dispute

PROFITS UP AT ITALIAN SORIN BIOMEDICA IN 1991

6 April 1992

Sorin Biomedica made net profits in 1991 of 12.3 billion lire ($9.9 billion), up from 11 billion lire in the...

GENENTECH REBUFFS ISIS-3 AND AWAITS GUSTO

6 April 1992

With the formal publication in The Lancet last week of the results of the ISIS-3 thrombolytic product trial, the major...

CORTECS' NSAID TARGETING STRATEGY

6 April 1992

Researchers at UK-based Cortecs Limited have published results of studies in volunteers concerning its technology aimed at improving the bioavailability...

INDIAN IBUPROFEN CHARGE DROPPED

6 April 1992

The US Department of Commerce has ceased its activities relating to claims of dumping and subsidies concerning imports into...

CHUGAI'S EPOCH

6 April 1992

A small study of Chugai's Epoch (recombinant erythropoietin) has found that while giving EPO to patients receiving autologous blood donation...

NEW DIRECTOR AT WHO

6 April 1992

Lionel Brisson of France has been appointed as director of program development and monitoring in the Office of the Director-General...

BIOSCIENCE/FUTURE MEDICAL DEAL

6 April 1992

Bioscience International has reached an agreement with Future Medical Products to begin testing of a product used to neutralize HIV....

EPIC REGISTRATION NOW OVER 1,300

6 April 1992

Speaking at the 12th International Symposium on Intensive Care and Emergency Medicine in Brussels, late last month, Andre Heyns, Roussel-...

EURO DRUGMAKERS STOCK "UNDERVALUED"

6 April 1992

Despite the enormous size of some Continental European pharmaceutical companies, they are being valued by their respective equity capital markets...

HERBAL MEDICINES IN ASIA 1992-96

6 April 1992

The international management consulting company McAlpine Thorpe and Warrier Ltd, which specializes in the field of herbal medicines, has announced...

Showing 94671-94680 of 95579 articles